Human IL-23 antigen binding proteins

• US 8,722,033 B2
• Filed: 10/26/2010
• Issued: 05/13/2014
• Est. Priority Date: 10/26/2009
• Status: Active Grant

• Current Assignee: Amgen Inc.
• Original Assignee: Amgen Inc.
• Inventors: Towne, Jennifer E., Cheng, Janet D., O'Neill, Jason C., Zhang, Yu, Cerne, Heather, Piper, Derek E., Ketchem, Randal R., Sun, Yu
• Primary Examiner(s): MERTZ, PREMA MARIA
• Application Number:
  US13/504,449
• Publication Number:
  US 20130004501A1
• Time in Patent Office: 1,295 Days
• Field of Search: None
• US Class Current: 424/85.2
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 39/395 Antibodies agglutinins A61K38/36 ; as drug carriers A61K47/50; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• CPC Class Codes: A61K 47/6845 the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: C07K 16/24 against cytokines, lymphokines or interferons
• CPC Class Codes: C07K 16/244 Interleukins [IL]
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/31 multispecific
• CPC Class Codes: C07K 2317/54 F(ab')2
• CPC Class Codes: C07K 2317/55 Fab or Fab'
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/622 Single chain antibody (scFv)
• CPC Class Codes: C07K 2317/626 Diabody or triabody
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.

Claims

1. An isolated antigen binding protein that binds IL-23, comprising at least one heavy chain variable region comprising:

a CDRH1 of SEQ ID NO;

91;

a CDRH2 of SEQ ID NO;

92; and

a CDRH3 of SEQ ID NO;

93; and

at least one light chain variable region comprising;

a CDRL1 of SEQ ID NO;

62;

a CDRL2 of SEQ ID NO;

63; and

a CDRL3 of SEQ ID NO;

64.

4. An isolated antigen binding protein of claim 1, 2 or 3 wherein said antigen binding protein has at least one property selected from the group consisting of:

a) reducing human IL-23 activity;

b) reducing production of a proinflammatory cytokine;

c) binding to human IL-23 with a K_D of less than or equal to 5×

10<sup>−

8</sup> M;

d) having a K_off rate of less than or equal to 5×

10<sup>−

6</sup> l/s; and

e) having an IC₅₀ of less than or equal to 400 pM.

5. A pharmaceutical composition comprising at least one antigen binding protein of claim 1, 2, or 3 and a pharmaceutically acceptable excipient.

6. A pharmaceutical composition comprising at least one antigen binding protein of claim 4 and a pharmaceutically acceptable excipient.

2. An isolated antigen binding protein that binds IL-23 comprising a heavy chain variable region comprising amino acid residues 31-35, 50-65 and 99-113 of SEQ ID NO:

31; and

a light chain variable region comprising amino acid residues 23-36, 52-58 and 91-101 of SEQ ID NO;

1.

3. An isolated antigen binding protein that binds IL-23 comprising

a heavy chain variable region of SEQ ID NO:

31 and

a light chain variable region of SEQ ID NO;

1.